Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

Now Viewing

EP: 1.Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

EP: 2.Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

EP: 3.Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

EP: 4.The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

EP: 5.Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

EP: 6.The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

EP: 7.Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC

EP: 8.The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment

EP: 9.Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

Video content above is prompted by the following:

Key Considerations for Selecting EGFR Inhibitor Treatment in Non–Small Cell Lung Cancer

Panel Introduction

• Moderator:Zosia Piotrowska, MD, MHS: Thoracic medical oncologist at Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
• Expert Panelist:Martin Dietrich, MD, PhD: Medical oncologist with the US Oncology Network, Orlando, Florida

Panel Expertise

Both experts are thoracic oncologists specializing in the treatment of non–small cell lung cancer (NSCLC), with particular focus on targeted therapies for EGFR-mutated disease.

First-Line Treatment Options for EGFR-Mutated NSCLC

Key Themes:

• Evolving Treatment Landscape: Recent clinical trials have shifted the standard of care from osimertinib monotherapy to combination approaches.
• Current Treatment Options: Discussion of NCCN guidelines listing osimertinib monotherapy as preferred Category 1, with combination therapies (FLAURA2 regimen of osimertinib plus chemotherapy and MARIPOSA regimen of amivantamab plus lazertinib) as other recommended options.
• Paradigm Shift: Both experts agree that combinations now outperform monotherapy, particularly for high-risk patients.

Notable Insights:

• Dr Dietrich: “We’ve seen 2 large phase 3 studies that have shown superiority to osimertinib, our gold standard for the better part of a decade.” He noted that the MARIPOSA trial demonstrated “a clinically quite remarkable overall survival benefit of 12 months.”
• Dr Piotrowska: While agreeing on the superiority of combinations, she emphasized that osimertinib monotherapy remains appropriate for certain patients, particularly “older patients with limited supports, those with impaired kidney function” or patients who “want to maximize quality of life and minimize time in the clinic.”